FIELD: biotechnology.
SUBSTANCE: invention relates to immunology and biotechnology. Presented is a cysteine-modified antibody-toxin conjugate having cytotoxic activity on tumour cells. Antibody contains an embedded cysteine in one or more cysteine embedding sites, which includes one or more of the positions of the constant region of the kappa/λ light chain 110, 111, 142, IgG heavy chain constant region positions 254, 255, 258, 259, 354, 355, 357, 378, 379, 386, 387 or 410 (number according to Kabat). Highly active cytotoxin is selected from MMAE, MMAF, PBD, SN-38, Dox.
EFFECT: invention enables to obtain a fixed-point antibody and a toxin and to achieve a toxin-to-antibody ratio (DAR) of 1,6 to 2 or 3,2 to 4.
8 cl, 20 dwg, 6 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| “CYSTEINE-MODIFIED ANTIBODY-DRUG” CONJUGATE AND ITS PRODUCTION METHOD | 2017 |
|
RU2762594C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
